Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19. This can be found at the link,’Antib…
-
General15 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News21 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business23 hours agoBell Potter names the best ASX shares to buy in October
-
General20 hours agoAustralia welcomes Gaza peace progress, hostage release